The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity
The poly(ADP-ribose) polymerase (PARP) inhibitor, Rubraca®, was given its first accelerated approval for BRCA-mutated ovarian cancer by the FDA at the end of 2016, and further approval by the FDA, EMA and NICE followed. Scientists at Newcastle University initiated the early stages, and seve...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/3/564 |
| _version_ | 1797763093150826496 |
|---|---|
| author | Nicola J Curtin |
| author_facet | Nicola J Curtin |
| author_sort | Nicola J Curtin |
| collection | DOAJ |
| description | The poly(ADP-ribose) polymerase (PARP) inhibitor, Rubraca®, was given its first accelerated approval for BRCA-mutated ovarian cancer by the FDA at the end of 2016, and further approval by the FDA, EMA and NICE followed. Scientists at Newcastle University initiated the early stages, and several collaborations with scientists in academia and the pharmaceutical industry enabled its final development to the approval stage. Although originally considered as a chemo- or radiosensitiser, its current application is as a single agent exploiting tumour-specific defects in DNA repair. As well as involving intellectual and physical effort, there have been a series of fortuitous occurrences and coincidences of timing that ensured its success. This review describes the history of the relationship between science and serendipity that brought us to the current position. |
| first_indexed | 2024-03-12T19:36:39Z |
| format | Article |
| id | doaj.art-92db380b8dcd42219e8289e5774bc4bf |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T19:36:39Z |
| publishDate | 2020-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-92db380b8dcd42219e8289e5774bc4bf2023-08-02T04:06:54ZengMDPI AGCancers2072-66942020-02-0112356410.3390/cancers12030564cancers12030564The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and SerendipityNicola J Curtin0Professor of Experimental Cancer Therapeutics, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Medical School, Paul O’Gorman Building, Newcastle University, Newcastle upon Tyne NE2 4HH, UKThe poly(ADP-ribose) polymerase (PARP) inhibitor, Rubraca®, was given its first accelerated approval for BRCA-mutated ovarian cancer by the FDA at the end of 2016, and further approval by the FDA, EMA and NICE followed. Scientists at Newcastle University initiated the early stages, and several collaborations with scientists in academia and the pharmaceutical industry enabled its final development to the approval stage. Although originally considered as a chemo- or radiosensitiser, its current application is as a single agent exploiting tumour-specific defects in DNA repair. As well as involving intellectual and physical effort, there have been a series of fortuitous occurrences and coincidences of timing that ensured its success. This review describes the history of the relationship between science and serendipity that brought us to the current position.https://www.mdpi.com/2072-6694/12/3/564parpdrug developmentsynthetic lethalityclinical trials |
| spellingShingle | Nicola J Curtin The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity Cancers parp drug development synthetic lethality clinical trials |
| title | The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity |
| title_full | The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity |
| title_fullStr | The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity |
| title_full_unstemmed | The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity |
| title_short | The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity |
| title_sort | development of rucaparib rubraca r a story of the synergy between science and serendipity |
| topic | parp drug development synthetic lethality clinical trials |
| url | https://www.mdpi.com/2072-6694/12/3/564 |
| work_keys_str_mv | AT nicolajcurtin thedevelopmentofrucaparibrubracaastoryofthesynergybetweenscienceandserendipity AT nicolajcurtin developmentofrucaparibrubracaastoryofthesynergybetweenscienceandserendipity |